Sickle Cell Disease Treatment Market Slated to Reach US$ 584.0 Million by 2025


A shift in lifestyle, rise in the aging populace in developed economies, in addition, to increase in disposable income in the emerging markets have boosted the healthcare spending along with the requirement for drug therapy together with blood transfusion and surgeries are aspects driving the growth of the global market. Other factors influencing the overall market include

  • Governments aim at creating awareness on the cure
  • Rising R&D activities in the developed countries
  • Decline in overall diagnosis cost
  • Mergers and licensing deals to share the R&D platform
  • Increased FDA approved drugs in the market

The worldwide market for sickle cell disease treatment is poised to reach a market valuation of US$ 584.0 Million by 2025, exhibiting a CAGR of 6.0 % in value terms throughout 2017-2025.

Market Segmentation by Drug Type

Based on the drug type, the worldwide sickle cell disease treatment market is categorized into,

  • Pain-relieving medications
  • Antibiotics
  • Hydroxyurea
  • Others

Among others, the hydroxyurea segment is projected to account for about 38.7 % market revenue share in 2017 and is considered to increase to 35.7% by the end of the forecast period 2025.

The sickle cell anemia is projected to account for the maximum market shares among other disease types followed by sickle beta thalassemia.

The overall market, based on the distribution channel is categorized into,

  • Online pharmacies
  • Retail pharmacies
  • Hospital pharmacies

The hospital pharmacies will be accounting for the maximum revenue shares throughout the forecast period, as a result of the rising direct procurement of drugs through governments to make sure accessibility in the hospital pharmacies. Retail pharmacies segment is likely to be the second largest distribution channels in the overall market during the said period.

The overall market is divided into five key regions namely, Latin America, North America, APAC, Europe and MEA. The Middle East and Africa will be the most lucrative market as a result of high occurrences of sickle cell diseases and exhibit a 6.1 % CAGR in value terms during the predicted period. The APAC region is also likely to witness growth and implementation of treatment for the sickle cell disease particularly in regions like India, creating a significant opportunity for the market players.

Request Sample Report

Leave a Reply